US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Prelude Therapeutics Incorporated - Common Stock (NQ:PRLD)

3.770 +0.100 (+2.72%)
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prelude Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Best Buy To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Thursday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
The Latest Analyst Ratings for Prelude Therapeutics ↗
 
Via Benzinga
News headline image
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Expert Ratings for Prelude Therapeutics ↗
 
Via Benzinga
Analyst Ratings for Prelude Therapeutics ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  Friday's session saw 169 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  Wednesday's session saw 150 companies set new 52-week lows. 
Via Benzinga
News headline image
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday, 27 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  During Thursday, 56 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  Friday's session saw 59 companies set new 52-week lows. 
Via Benzinga
News headline image
Prelude Therapeutics To Participate in Jefferies Healthcare Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Prelude Therapeutics Announces Pricing of Public Offering
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Launch of Proposed Public Offering
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
Eight Abstracts Demonstrate Progress of Prelude’s Differentiated Pipeline 
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
The 7 Worst Stocks to Buy Now ↗
With the market reeling from the banking crisis, even hardened gamblers should avoid these worst stocks to buy now. 
Via InvestorPlace
News headline image
Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Therapeutics To Participate in Barclays Global Healthcare Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group. 
Via Benzinga
News headline image
Carvana, Crocs And Other Big Losers From Monday ↗
U.S. stocks closed lower on Monday, with the Nasdaq dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
News headline image
Why This Prelude Therapeutics Analyst Disagrees With 2 Others And Downgraded The Stock ↗
Shares of Prelude Therapeutics Inc (NASDAQ: PRLD) came under pressure during early trading on Monday. 
Via Benzinga
News headline image
Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
News headline image
Marten Transport, Silvergate Capital And Some Other Big Stocks Moving Lower On Tuesday ↗
U.S. stocks traded higher, with the Dow Jones gaining more than 250 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
Phase 1 Study Will Include Biomarker Selected Patients with Advanced Solid Tumors 
From Prelude Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >